NCT04084366 - Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions

Locally Advanced Solid Tumor

Interventions

DRUG

OBI-999

For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.

DRUG

OBI-999

For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

West Cancer Center, Germantown

University of Texas MD Anderson Cancer Center, Houston

Scripps MD Anderson Cancer Center, La Jolla